Akorn price target raised to $33 from $30 at Piper Jaffray Piper Jaffray raised its price target for Akorn shares to $33 to reflect the company's acquisition of VersaPharm. Piper believes Akorn has one of the most attractive long-term growth profiles in the broader specialty pharma space and it keeps an Overweight rating on the stock.
Akorn initiated with Outperform, $50 target at William Blair William Blair started shares of Akorn with an Outperform rating and $50 price target. The firm says the maker of ophthalmic and hospital-based injectable therapies is one of the fastest-growing companies in the specialty pharmaceuticals sector. William Blair thinks consolidation will likely continue within the specialty/generics market and feels Akorn represents an attractive asset. The stock closed yesterday up 38c to $39.75.